Perspective · 4 Aug 2023
CommentaryPublished 3 Feb 2023
Therapies Target Pulmonary Endothelial Dysfunction
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Since the late 1990s, a number of drugs have been developed that have been shown to be effective in phase 3 randomised controlled trials, despite the fact that pulmonary arterial hypertension is a rare condition. The prognosis for pulmonary arterial hypertension remains poor despite significant advancements in treatment. With vasodilation and anti-proliferative effects, current treatments target pulmonary endothelial dysfunction. Urgently needed are new treatments that affect important outcomes and target proliferative vascular remodelling. In order to conduct thorough research on each and every emerging candidate therapy, additional advancements in the design of clinical trials are required. The primary endpoint of pulmonary arterial hypertension trials is now larger clinical event-driven trial outcomes rather than short-term submaximal exercise capacity. Due to the need for larger sample sizes and longer follow-up periods, which would be problematic in such a rare disease, event-driven pulmonary arterial hypertension trials may face feasibility and efficiency issues in the future. Enhancement strategies, novel trial endpoints, and novel trial designs all have the potential to boost the efficiency of upcoming studies on pulmonary arterial hypertension while maintaining robustness and clinically relevant evidence. The gasotransmitter family includes Hydrogen Sulfide (H2S), carbon monoxide, and nitric oxide. By regulating vascular tone, sympathetic nervous system activity, and renal sodium excretion, H2S is involved in controlling blood pressure. Mice that lack the enzyme Cystathionine -Lyase (CSE), which is involved in the production of H2S in the cardiovascular system, develop moderate age-dependent hypertension as well as endothelial dysfunction. In the most common animal models of hypertension, such as spontaneously hypertensive rats, Dahl salt-sensitive rats, chronic administration of NO synthase inhibitors, angiotensin II infusion, and two-kidney-one-clip hypertension, the model of renovascular hypertension, decreased H2S concentration, as well as the expression and activities of H2S-producing enzymes. In these models, H2S donors lower blood pressure, but in animals with normal blood pressure, they have no significant effect.
Keywords
Subjects
Public Health & EpidemiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 1 Apr 2023
Novel Therapeutic Approaches for Neurogenic Pulmonary Edema: Targeting Endothelial Dysfunction and Oxidative Stress.
Article · 2012
Value of Endothelial Dysfunction in the Pathogenesis of Portal Hypertension
Mini review · 29 Aug 2023
Exploring the Relationship between Exercise Performance, Endothelial Dysfunction and Pulmonary Hypertension in OSA
Perspective · 28 Aug 2023
Pulmonary hypertension: A paradigm of endothelial dysfunction
More from this journal
The newest in Journal of Preventive Medicine.
Research article · 17 Oct 2025
Addressing Gender Differences and Colon Cancer Screening Disparities in Spanish-preferred Populations
Opinion · 27 May 2025
The Role and Scope of Healthcare Systems: Ensuring Access, Wellness, and Public Health
Opinion · 27 May 2025
Preventing Tobacco Use: A Public Health Approach to Reducing Smoking-Related Diseases
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Preventive Medicine
- SubjectPublic Health & Epidemiology
- BylineArticles whose byline prints “Hopper Yuan”

